ALLOGENE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.9 USD | +5.07% |
|
-3.65% | -9.66% |
| May. 13 | Allogene Therapeutics Prices $110 Million Offering | MT |
| May. 13 | Allogene Therapeutics Q1 Loss Narrows, Revenue Declines | MT |
Presenter SpeechCory Kasimov (Analysts)All right. Good afternoon from the 40th Annual JPMorgan...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
2.76
USD
Average target price
11.66
USD
Spread / Average Target
+322.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.66% | 471M | |
| +5.66% | 109B | |
| +11.23% | 105B | |
| -0.38% | 22.25B | |
| -12.15% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.09% | 16.85B | |
| +3.33% | 13.76B | |
| +36.58% | 12.46B |
- Stock Market
- Equities
- ALLO Stock
- News Allogene Therapeutics, Inc.
- Transcript : Allogene Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-11-2022 03
